FibroGen Board, Officers Sued In Del. Over Drug Missteps
A FibroGen Inc. stockholder has hit the biopharmaceutical venture's board and top officers with a derivative suit in Delaware's Chancery Court, alleging breaches of fiduciary duty and insider trading in connection...To view the full article, register now.
Already a subscriber? Click here to view full article